Methadon Martindale Pharma (Methadone Hydrochloride)

Methadone is used within the opioid‑dependence and pain‑management pathways to provide long‑acting opioid activity.

• Opioid dependence: maintenance therapy that reduces withdrawal symptoms and cravings.
• Severe chronic pain: provides sustained analgesia for patients requiring strong opioid control.
• Opioid detoxification: facilitates a controlled tapering process under medical supervision.

• Methadone acts as a full agonist at the mu‑opioid receptor, producing analgesia and suppressing opioid withdrawal. It also blocks NMDA receptors and inhibits the reuptake of serotonin and norepinephrine, contributing to its efficacy in pain modulation and dependence treatment. Metabolism occurs primarily via hepatic CYP3A4, CYP2B6 and CYP2D6 enzymes, with renal excretion of metabolites.

Methadone may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects

• Constipation: reduced gastrointestinal motility.
• Nausea: transient upset stomach.
• Drowsiness: increased sedation.
• Sweating: excessive perspiration.
• Dry mouth: reduced salivation.
• Weight gain: increased appetite.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be fatal.
• QT interval prolongation: risk of cardiac arrhythmia.
• Seizures: rare convulsive episodes.
• Severe hypotension: dangerous drop in blood pressure.
• Adrenal insufficiency: impaired cortisol production.

When prescribing methadone, clinicians should consider several safety measures.

• Cardiac assessment: evaluate QT interval and correct electrolyte abnormalities.
• Respiratory monitoring: observe for signs of depression, especially after dose changes.
• Hepatic function: adjust dosing in patients with liver impairment.
• Substance misuse history: screen for concurrent opioid or CNS depressant use.
• Acute severe asthma: avoid use due to risk of bronchospasm.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Methadone interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid)

• Benzodiazepines: additive CNS depression.
• MAO inhibitors: risk of severe serotonin syndrome.
• QT‑prolonging agents: increased arrhythmia risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): elevated methadone levels.
• Other opioids: heightened respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): reduced methadone exposure.
• Selective serotonin reuptake inhibitors: potential serotonin syndrome.
• Antihistamines: enhanced sedation.
• Diuretics: possible electrolyte shifts affecting cardiac rhythm.
• Alcohol: additive CNS depression.